BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for the proposed initial public offering in the United States of American Depositary Shares (“ADSs”) representing ordinary shares of Anchiano Therapeutics. The number and value of ADSs to be offered have not yet been determined.

The proposed U.S. IPO is expected to commence as market conditions permit and is subject to the SEC's review and declaration of effectiveness of the filing.

This announcement is made pursuant to, and in accordance with, Rule 135 of the Securities Act of 1933. This announcement does not, and is not intended to, constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States or elsewhere, and it does not, and is not intended to, constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Company Contact:

Frank Haluska, M.D., Ph.D.

President and Chief Executive Officer

Investor Contact:

Ashley R. Robinson

Managing Director

LifeSci Advisors, LLC

617-535-7742

EN
07/01/2019

Underlying

BCNLFBIOCANCELL LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOCANCELL LTD

 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Closing of $30.5 Million Initial Publ...

Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS resulting in gross proceeds of $30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019. The underwriters have been granted a 30-day option ...

February 14, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Publi...

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to clos...

February 12, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Filing of F-1 Registration Statement f...

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for the proposed initial public offering in the United States of American Depositary Shares (“ADSs”) representing ordinary shares of Anchiano Therapeutics. The numbe...

January 7, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study ...

Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the initiation of Codex, the Company's pivotal Phase 2 study of inodiftagene vixteplasmid (BC-819), a first-in-class gene therapy for patients with non-muscle-invasive bladder cancer (NMIBC). The study will enroll 140 patients wit...

December 18, 2018 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as N...

Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company’s new Chief Medical Officer. Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies. “We are thrilled to have David, a skilled medical lead and ac...

November 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch